Development of JAK2V617F-positive polycythemia vera after chemotherapy-induced remission of primary central nervous system diffuse large B cell non-Hodgkin's lymphoma: a case report and review of the literature

Acta Haematol. 2013;130(3):142-5. doi: 10.1159/000347159. Epub 2013 May 7.

Abstract

The coexistence or the development of Philadelphia chromosome-negative myeloproliferative neoplasms after a lymphoproliferative disease in the same patient is an extremely rare event. We report the case of a 72-year-old man who developed JAK2V617F polycythemia vera 3 years after the diagnosis and treatment of primary diffuse large B cell non-Hodgkin's lymphoma of the central nervous system. We also review the literature regarding the pathogenesis underlying the association of myeloproliferative and lymphoproliferative chronic disorders.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Amino Acid Substitution
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Central Nervous System Neoplasms / diagnosis
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / genetics
  • Cytarabine
  • Humans
  • Janus Kinase 2 / genetics*
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Male
  • Methotrexate
  • Mutation, Missense*
  • Polycythemia Vera / chemically induced*
  • Polycythemia Vera / diagnosis
  • Polycythemia Vera / genetics*

Substances

  • Cytarabine
  • JAK2 protein, human
  • Janus Kinase 2
  • Methotrexate